Breaking News

NCI studying ivermectin's 'ability to kill cancer cells,' alarming scientists

February 10, 2026
LUIS ROBAYO/AFP via Getty Images)

National Cancer Institute studying ivermectin's 'ability to kill cancer cells,' alarming career scientists

NCI Director Anthony Letai cites public interest in starting a preclinical study on ivermectin. One cancer researcher 'shocked and appalled' at the news.

By Rachana Pradhan | KFF Health News


TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics

STAT analysis: Trump says TrumpRx has the world's lowest drug prices, but many listed drugs are cheaper as generics elsewhere.

By John Wilkerson, J. Emory Parker, Chelsea Cirruzzo, Elaine Chen, and Daniel Payne


STAT+ | Trump administration revives effort to launch pilot initiative reworking drug discount program

The American Hospital Association and several hospital systems had filed a lawsuit arguing the government rushed to start a pilot.

By Ed Silverman



Scott Olson/Getty Images

STAT+ | Eli Lilly to buy Orna Therapeutics for $2.4 billion

Eli Lilly will pay up to $2.4 billion for the biotechnology firm, the latest in a string of deals that the pharmaceutical giant has made in the past year.

By Matthew Herper


More around STAT

In case you missed it

  • FDA warned a Hims & Hers compounder after finding bugs and failing to report a serious side effect, STAT
  • Strong cancer drug sales boost AstraZeneca earnings, Financial Times
  • Catherine O'Hara died from a pulmonary embolism. Cancer was the underlying cause, Associated Press

Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments